Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder Cancer: the CRIMI study.

Trial Profile

A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder Cancer: the CRIMI study.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Mitomycin
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CRIMI
  • Most Recent Events

    • 04 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top